Nasdaq · CIK 0001711279 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Krystal Biotech, Inc.
KRYS chart by TradingView
PRICE HISTORY
LIVE · NASDAQKRYS chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $0.4B
- EBITDA
- $0.2B
- FREE CASH FLOW
- $0.2B
- EPS
- $6.84
- GROSS MARGIN
- —
- ROIC
- —
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 15 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
47.2x
-86%26.5x327.9x
⤢
P / SALES (TTM)
25.9x
-93%11.4x391.7x
⤢
P / BOOK
8.4x
+154%3.3x8.4x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
⤢
FCF YIELD (TTM)
2.26%
+6.0pp-3.74%4.53%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.1B
+$0.1B⤢
EBITDA (DERIVED)
$0.1B
+$0.1B⤢
NET INCOME
$0.1B
+$0.1B⤢
EPS (DILUTED)
$1.79
+$2.95⤢
REVENUE GROWTH YOY
24.14%
-855.8pp16.65%879.91%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
59.74%
+328.6pp-268.90%70.37%
⤢
RETURN ON CAPITAL
—
⤢
RETURN ON EQUITY (TTM)
17.77%
+21.4pp-3.65%17.77%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN—
OPERATING MARGIN49.00%
NET MARGIN45.94%
FCF MARGIN59.74%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.1B
+$0.1B⤢
STOCK-BASED COMP
$0.0B
+56%⤢
CAPITAL EXPENDITURE
$0.0B
-75%⤢
SHARES OUTSTANDING
0.03B
+20%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.4B
+129%⤢
TOTAL DEBT
—
⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 101.09%INSIDERS 10.93%OTHER / RETAIL 0.00%552 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| FMR, LLC | 14.78% | 4.4M | $1.43B | +0.6% |
| Blackrock Inc. | 13.31% | 3.9M | $1.29B | +0.1% |
| Avoro Capital Advisors LLC | 9.76% | 2.9M | $943.1M | +0.0% |
| Vanguard Portfolio Management LLC | 4.92% | 1.5M | $475.5M | NEW |
| State Street Corporation | 4.44% | 1.3M | $429.1M | -2.1% |
| Vanguard Capital Management LLC | 3.94% | 1.2M | $380.4M | NEW |
| Soleus Capital Management, L.P. | 3.90% | 1.2M | $376.4M | +22.5% |
| Capital World Investors | 2.79% | 825K | $269.2M | +1.9% |
| Redmile Group, LLC | 2.28% | 674K | $219.9M | -0.6% |
| Geode Capital Management, LLC | 2.18% | 644K | $210.2M | +5.3% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.